Answers are grounded in this paper and cite their sources.
Identifies high-risk endometrial cancer groups for follow-up, suggesting effective treatment decisions using risk classification.
ECOG performance status is an accessible, low-cost clinical parameter that can be effectively integrated with the ESMO-ESGO-ESTRO risk classification to guide treatment decisions and identify high-risk patients for closer follow-up. In settings where molecular classification is not feasible, the 2016 risk stratification remains a reliable tool for therapeutic planning.
No takes yet. Share an insight, caveat, or question.
Elçiçek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: